ClinicalTrials.gg
RecruitingNCT07580950Updated May 12, 2026

The Research of Integrated Traditional Chinese and Western Medicine on Hypothalamic Amenorrhea

A Phase 4 interventional study of traditional Chinese medicine and Western medicine in Functional Hypothalamic Amenorrhea, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to female participants aged 14 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Peking Union Medical College Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Oct 2025, registered Apr 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
14 Years to 40 Years
Sex
Female
01

Study summary

This study aims to validate the efficacy and safety of the "two-step cycle-regulating approach integrating Chinese and Western medicine: rapid restoration of menstruation with Western medicine, and nourish the kidney and soothe the liver, nourishing the essence, and reinforcing the vital essence and strengthening the primordial qi with Chinese medicine" through a nationwide randomized controlled clinical trial involving 210 cases. Guided by traditional Chinese medicine theory, the study will explore the mechanism of integrated Chinese and Western medicine in the treatment of functional hypothalamic amenorrhea through gut microbiota and metabolomics research.

02

Conditions studied

  • Functional Hypothalamic Amenorrhea

Browse trials for

Keywords

  • Functional Hypothalamic Amenorrhea
  • Integrated Traditional Chinese and Western Clinical Medicine
  • Randomized controlled trial
03

In context

Amenorrhea

80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.

This study's planned enrollment of 210 is above the median of 54 across 49 interventional studies indexed under Amenorrhea.

Browse Amenorrhea studies →

Lead sponsor

Peking Union Medical College Hospital is the lead sponsor of 1,158 studies on the registry; 477 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Diagnostic criteria for functional hypothalamic amenorrhea

  1. primary or secondary amenorrhea
  2. Normal or low FSH levels, LH \< 5 IU/L, E2 \< 50 pg/mL
  3. Exclusion of amenorrhea caused by: -Organic lesions of the hypothalamus or pituitary gland , Ovarian amenorrhea , Uterine or lower genital tract developmental abnormalities ,Drug-induced amenorrhea ,Other causes of amenorrhea

Exclusion criteria

Exclusion Criteria:

  1. Individuals who have used relevant medications within the past 3 months
  2. History of substance abuse or dependence (alcohol or drugs) within the past 3 months; heavy smokers (those consuming 20 or more cigarettes daily)
  3. Individuals with severe or unstable physical illnesses, including liver, kidney, gastrointestinal, cardiovascular, cerebrovascular, respiratory, endocrine, neurological, immune, or hematological disorders; psychiatric patients
  4. Lactating or pregnant women, or females within one year postpartum
  5. History of allergy to the drug; to Dingkundan, Bazhen Yimu Pills, or Femoston
  6. Individuals with or suspected of having estrogen-sensitive tumors (e.g., endometrial cancer, breast cancer).
  7. History of thromboembolic disease or thrombotic tendency.
  8. Participation in another investigational drug clinical trial within 1 month prior to inclusion in this study (first interview).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
210 participants (estimated)

Study arms

  • Active comparator
    Femoston group

    Femoston 2/10 (estradiol 2mg / dydrogesterone 10mg), 1 tablet daily.

    Drug: Western medicine

  • Experimental
    Ba Zhen Yi Mu Pill and Ding Kun Dan group

    Participants received Traditional Chinese medicine Ba Zhen Yi Mu Pill (6g three times daily) and Ding Kun Dan (7g twice daily) concurrently.

    Drug: traditional Chinese medicine

  • Experimental
    Ba Zhen Yi Mu Pill and Ding Kun Dan combined with Femoston group

    Participants in the intervention group received Ba Zhen Yi Mu Pill (6 g twice daily), Ding Kun Dan (7g twice daily), and Femoston (estradiol 2mg / dydrogesterone 10mg, 1 tablet daily) concurrently.

    Drug: traditional Chinese medicine · Drug: Western medicine

Interventions

06

What researchers measure

Primary outcomes

  1. Menstrual patterns during treatment and after discontinuation

    Document the number of episodes of menstruation during the treatment and follow-up period

    Time frame: From enrollment, during the treatment of 6 months, and within 3 months after treatment

  2. Sex hormone levels

    Measure the levels of sex hormones in the blood, including Follicle-Stimulating Hormone (FSH), Luteinizing Hormone (LH), Estradiol (E2), Progesterone (P), Prolactin (PRL), Dehydroepiandrosterone Sulfate (DHEA-S), and Anti-Müllerian Hormone (AMH).

    Time frame: from enrollment to the end of treatment at 6 months

  3. Uterine volume

    Uterine volume was calculated using the length, width, and anteroposterior diameter measured by ultrasound, according to the formula Volume = 0.5233 × L × W × AP, where L, W, and AP represent the length, width, and anteroposterior diameter of the uterus measured by ultrasound.

    Time frame: From enrollment to the end of treatment at 6 months

  4. Quality of Life Score(36-Item Short Form Health Survey,SF 36)

    The SF-36 (36-Item Short Form Health Survey) score ranges from 0 to 100, where higher scores represent better quality of life outcomes.

    Time frame: From enrollment to the end of treatment at 6 months

  5. Total ovarian volume

    Total ovarian volume (cm³) was calculated by summing the volumes of the left and right ovaries, each of which was derived using the ellipsoid formula: V = 0.523 × length × width × thickness .The three perpendicular diameters of the ovary (length, width, and thickness) were measured using ultrasound.

    Time frame: from enrollment to the end of treatment at 6 months

Secondary outcomes

  1. Depressive symptoms were assessed using the Beck Depression Inventory-II (BDI-II)

    Depressive symptoms were assessed using the Beck Depression Inventory-II (BDI-II). Total scores range from 0 to 63, with higher scores indicating more severe depressive symptoms (worse outcome).

    Time frame: From enrollment to 3 months after the end of treatment

  2. Anxiety symptoms were assessed using the Generalized Anxiety Disorder 7-item (GAD-7) scale.

    Anxiety symptoms were assessed using the Generalized Anxiety Disorder 7-item (GAD-7) scale. Total scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms (worse outcome).

    Time frame: From enrollment to 3 months after the end of treatment

  3. Perceived stress was assessed using the 10-item Perceived Stress Scale (PSS-10)

    Perceived stress was assessed using the 10-item Perceived Stress Scale (PSS-10). Total scores range from 0 to 40, with higher scores indicating greater perceived stress (worse outcome).

    Time frame: From enrollment to 3 months after the end of treatment

  4. Disordered eating attitudes and behaviors were assessed using the 26-item Eating Attitudes Test (EAT-26)

    Disordered eating attitudes and behaviors were assessed using the 26-item Eating Attitudes Test (EAT-26) . Total scores range from 0 to 78 , with higher scores indicating more disordered eating pathology (worse outcome) . A score of 20 or higher is considered indicative of an elevated risk for an eating disorder, warranting further clinical evaluation

    Time frame: From enrollment to 3 months after the end of treatment

Other outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Participants were followed up at the hospital every 3 months during the treatment period. At each follow-up visit, adverse events (AEs) were documented, and their causality (relationship to the treatment) was assessed by the investigators. The severity of AEs was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

    Time frame: From enrollment to the end of treatment at 6 months

  2. Serum alanine aminotransferase (ALT) levels were measured to assess liver function.

    Serum alanine aminotransferase (ALT) levels were measured to assess liver function. Elevated ALT levels indicate hepatocellular injury (worse outcome).

    Time frame: From enrollment to 3 months after the end of treatment.

  3. Renal function was assessed by measuring serum creatinine (SCr) levels

    Renal function was assessed by measuring serum creatinine (SCr) levels. Serum creatinine levels were measured, with higher levels indicating worse renal function (worse outcome) .

    Time frame: From enrollment to 3 months after the end of treatment

  4. Physical activity was assessed using the short form of the International Physical Activity Questionnaire (IPAQ-SF) .

    Physical activity was assessed using the short form of the International Physical Activity Questionnaire (IPAQ-SF) . Total physical activity was calculated as metabolic equivalent of task (MET)-minutes per week, ranging from 0 to 14,280 MET-minutes/week (theoretical maximum), with higher scores indicating greater physical activity levels (better outcome) . Total sitting time was recorded as minutes per week, ranging from 0 to 1,440 minutes/week, with higher scores indicating more sedentary behavior (worse outcome) .

    Time frame: From enrollment to 3 months after the end of treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Jun 2028, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2026
First posted
May 12, 2026
StartActual
Oct 22, 2025
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2028
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07580950
Collaborators
Peking University Third Hospital, Dongfang Hospital Beijing University of Chinese Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, Shenyang Women's and Children's Hospital, Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing University of Chinese Medicine
Responsible party
Sponsor
First posted
May 12, 2026
Start date
Oct 22, 2025
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
May 12, 2026

Study contacts

Yan Deng, Doctor
Contact
yanndeng@163.com
86+010-69158331

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Drugs, Chinese Herbal

Start the discussion